TNFSF18 and B-cell chronic lymphocytic leukemia: In addition, GITRL contributed to resistance of CLL cells to rituximab therapy, indicating that GITR/GITRL contributes to disease progression and resistance to Rituximab-induced NK reactivity in CLL [29].